Evaluation of lipid oxidative stress status in Sjögren syndrome patients

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 201-210

  Wakamatsu, Tais H ^a   Dogru, Murat ^a,b   Matsumoto, Yukihiro ^a   Kojima, Takashi ^a   Kaido, Minako ^a   Ibrahim, Osama M A ^a   Sato, Enrique A ^a   Igarashi, Ayako ^b   Ichihashi, Yoshiyuki ^a   Satake, Yoshiyuki ^b   Shimazaki, Jun ^b   Tsubota, Kazuo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONJUNCTIVA; CONTROLLED STUDY; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LACRIMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIRMER TEST; SJOEGREN SYNDROME; TEAR FILM; IMMUNOLOGY; INFLAMMATION; LACRIMAL FLUID; LIPID PEROXIDATION; MALE; METABOLISM; MIDDLE AGED;

4 HYDROXYNONENAL; 4-HYDROXY-2-NONENAL; ALDEHYDE; BIOLOGICAL MARKER; LYSINE; N(EPSILON) HEXANOYLLYSINE; N(EPSILON)-HEXANOYLLYSINE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; AGED, 80 AND OVER; ALDEHYDES; BIOLOGICAL MARKERS; CONJUNCTIVA; FEMALE; HUMANS; INFLAMMATION; LIPID PEROXIDATION; LYSINE; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; SJOGREN'S SYNDROME; TEARS;

MLCS; MLOWN;

EID: 84874523035     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10325     Document Type: Article

References (57)

1. Carsons S. A review and update of Sjögren's syndrome: manifestations, diagnosis, and treatment. Am J Manag Care. 2001;7:S433-S443.
2. Jonsson R, Moen K, Vestrheim D, Szodoray P. Current issues in Sjögren's syndrome. Oral Dis. 2002;8:130-140.
3. Foster CS, Azar DT, Dohlman CH. Sjogren's Syndrome. In: The Cornea-Scientific Foundation & Clinical Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:629.
4. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292.
5. Miyata T, Ishiguro N, Yasuda Y, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun. 1998; 244:45-49.
6. Staron A, Makosa G, Koter-Michalak M. Oxidative stress in erythrocytes from patients with rheumatoid arthritis. Rheumatol Int. 2012;32:331-334.
7. Phillips DC, Dias HK, Kitas GD, Griffiths HR. Aberrant reactive oxygen and nitrogen species generation in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival, and therapeutic intervention. Antioxid Redox Signal. 2010;12:743-785.
8. Mukhopadhyay S, Sen S, Majhi B, Das KP, Kar M. Methyl glyoxal elevation is associated with oxidative stress in rheumatoid arthritis. Free Radic Res. 2007;41:507-514.
9. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren's syndrome (1999): availability and validity. Mod Rheumatol. 2004;14;425-434.
10. Yukari J. AD Classification of Fluorescein Staining. Tokyo: Bunkodo; Practical Ophthalmology; 1998:1-61 (Japanese).
11. Toda I, Tsubota K. Practical double vital staining for ocular surface evaluation. Cornea. 1993;12:366-367.
12. Leibowitz HM, Villazon S. Corneal Disorders. Philadelphia: WB Saunders; 1998:983-984.
13. Kato Y, Miyake Y, Yamamoto K, et al. Preparation of a monoclonal antibody to N(epsilon)-(hexanonyl)lysine: application to the evaluation of protective effects of flavonoid supplementation against exercise-induced oxidative stress in rat skeletal muscle. Biochem Biophys Res Commun. 2000; 274:389-393.
14. Wakamatsu TH, Dogru M, Ayako I, et al. Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease. Mol Vis. 16:2465-2475.
15. Gao X, Zhang H, Belmadani S, et al. Role of TNF-alpha-induced reactive oxygen species in endothelial dysfunction during reperfusion injury. Am J Physiol Heart Circ Physiol. 2008;295: H2242-H2249.
16. Fraczek M, Sanocka D, Kamieniczna M, Kurpisz M. Proinflammatory cytokines as an intermediate factor enhancing lipid sperm membrane peroxidation in in vitro conditions. J Androl. 2008;29:85-92.
17. Basuroy S, Bhattacharya S, Leffler CW, Parfenova H. Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol. 2009;296:C422-C432.
18. Eleuteri E, Magno F, Gnemmi I, et al. Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Front Biosci. 2009;14:2230-2237.
19. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009;73:411-418.
20. Tsuboi H, Kouda K, Takeuchi H, et al. 8-hydroxydeoxyguanosine in urine as an index of oxidative damage to DNA in the evaluation of atopic dermatitis. Br J Dermatol. 1998;138: 1033-1035.
21. Tsukahara H, Shibata R, Ohshima Y, et al. Oxidative stress and altered antioxidant defenses in children with acute exacerbation of atopic dermatitis. Life Sci. 2003;72:2509-2516.
22. Bashir S, Harris G, Denman MA, Blake DR, Winyard PG. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis. 1993; 52:659-666.
23. Wanchu A, Khullar M, Sud A, Bambery P. Elevated nitric oxide production in patients with primary Sjögren's syndrome. Clin Rheumatol. 2000;19:360-364.
24. Bohanec Grabar P, Logar D, Tomsic M, Rozman B, Dolzan V. Genetic polymorphisms modifying oxidative stress are associated with disease activity in rheumatoid arthritis patients. Dis Markers. 2009;26:41-48.
25. Caulfield VL, Balmer C, Dawson LJ, Smith PM. A role for nitric oxide-mediated glandular hypofunction in a non-apoptotic model for Sjögren's syndrome. Rheumatology (Oxford). 2009; 48:727-733.
26. Giusti L, Baldini C, Bazzichi L, et al. Proteome analysis of whole saliva: a new tool for rheumatic diseases-the example of Sjögren's syndrome. Proteomics. 2007;7:1634-1643.
27. Ryo K, Yamada H, Nakagawa Y, et al. Possible involvement of oxidative stress in salivary gland of patients with Sjögren's syndrome. Pathobiology. 2006;73:252-260.
28. Gringhuis SI, Leow A, Papendrecht-Van Der Voort EA, Remans PH, Breedveld FC, Verweij CL. Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J Immunol. 2000; 164:2170-2179.
29. Gringhuis SI, Breedveld FC, Verweij CL. Linker for activation of T cells: sensing redox imbalance. Methods Enzymol. 2002; 352:248-257.
30. Kurimoto C, Kawano S, Tsuji G, et al. Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjögren's syndrome. J Rheumatol. 2007;34:2035-2043.
31. Koufuchi R. possible involvement of oxidative stress in salivary gland of patients with Sjögren's syndrome. Pathobiology. 2006;73:252-260.
32. Lemarechal H, Anract P, Beaudeux JL, Bonnefont-Rousselot D, Ekindjian OG, Borderie D. Impairment of thioredoxin reductase activity by oxidative stress in human rheumatoid synoviocytes. Free Radic Res. 2007;41:688-698.
33. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609-2614.
34. Saegusa J, Kawano S, Koshiba M, et al. Oxidative stress mediates cell surface expression of SS-A/Ro antigen on keratinocytes. Free Radic Biol Med. 2002;32:1006-1016.
35. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis. 1999; 5:32.
36. Imamura Y, Noda S, Hashizume K, et al. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. Proc Natl Acad Sci U S A. 2006;103:11282-11287.
37. Spector A. Oxidative stress-induced cataract: mechanism of action. Faseb J. 1995;9:1173-1182.
38. Choudhary S, Xiao T, Vergara LA, et al. Role of aldehyde dehydrogenase isozymes in the defense of rat lens and human lens epithelial cells against oxidative stress. Invest Ophthalmol Vis Sci. 2005;46:259-267.
39. Gritz DC, Montes C, Atalla LR, Wu GS, Sevanian A, Rao NA. Histochemical localization of superoxide production in experimental autoimmune uveitis. Curr Eye Res. 1991;10: 927-931.
40. Niesman MR, Johnson KA, Penn JS. Therapeutic effect of liposomal superoxide dismutase in an animal model of retinopathy of prematurity. Neurochem Res. 1997;22:597-605.
41. Behndig A, Karlsson K, Johansson BO, Brannstrom T, Marklund SL. Superoxide dismutase isoenzymes in the normal and diseased human cornea. Invest Ophthalmol Vis Sci. 2001; 42:2293-2296.
42. Alio JL, Ayala MJ, Mulet ME, Artola A, Ruiz JM, Bellot J. Antioxidant therapy in the treatment of experimental acute corneal inflammation. Ophthalmic Res. 1995;27:136-143.
43. Alio JL, Artola A, Serra A, Ayala MJ, Mulet ME. Effect of topical antioxidant therapy on experimental infectious keratitis. Cornea. 1995;14:175-179.
44. Wakamatsu TH. Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease. Mol Vis. 2010; 16:2465-2475.
45. Ward SK, Wakamatsu TH, Dogru M, et al. The role of oxidative stress and inflammation in conjunctivochalasis. Invest Ophthalmol Vis Sci. 2010;51:1994-2002.
46. Nakamura S, Shibuya M, Nakashima H, et al. Involvement of oxidative stress on corneal epithelial alterations in a blinksuppressed dry eye. Invest Ophthalmol Vis Sci. 2007;48: 1552-1558.
47. Augustin AJ, Spitznas M, Kaviani N, et al. Oxidative reactions in the tear fluid of patients suffering from dry eyes. Graefes Arch Clin Exp Ophthalmol. 1995;233:694-698.
48. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res. 2003;42:318-343.
49. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-128.
50. Eckl PM, Ortner A, Esterbauer H. Genotoxic properties of 4-hydroxyalkenals and analogous aldehydes. Mutat Res. 1993; 290:183-192.
51. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008;4:697-720.
52. Black W, Chen Y, Matsumoto A, et al. Molecular mechanisms of ALDH3A1-mediated cellular protection against 4-hydroxy-2-nonenal. Free Radic Biol Med. 2012;52:1937-1944.
53. Cejkova J, Ardan T, Simonova Z, et al. Decreased expression of antioxidant enzymes in the conjunctival epithelium of dry eye (Sjögren's syndrome) and its possible contribution to the development of ocular surface oxidative injuries. Histol Histopathol. 2008;23:1477-1483.
54. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52:601-623.
55. Bonafede RP, Downey DC, Bennett RM. An association of fibromyalgia with primary Sjögren's syndrome: a prospective study of 72 patients. J Rheumatol. 1995;22:133-136.
56. Daniels TE, Whitcher JP. Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca. Analysis of 618 patients with suspected Sjögren's syndrome. Arthritis Rheum. 1994;37:869-877.
57. Gao J, Schwalb TA, Addeo JV, Ghosn CR, Stern ME. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea. 1998;17:654-663.